by admin | Jul 12, 2024 | Company news
BOSTON, MA, JULY 12, 2024 – Jim Graham and Christian Boada of Qana Therapeutics participated in the NIH I-Corps program kickoff in Boston. The I-Corps™ program was created by the NSF in 2011 to help move academic research it has funded to market. I-Corps offers select...
by admin | Apr 18, 2024 | Company news
Senior Scientist, Dr. Christian Boada, represented Qana at the BioFest Invest Pitch Competition in San Antonio. SAN ANTONIO, TEXAS, April 17, 2024 – Qana Therapeutics participated in the BioMedSA BioFest Invest pitch competition. BioFest Invest is an annual spring...
by admin | Apr 3, 2024 | Company news
Award will fund development of Qana’s metabolically-targeted therapeutic for adrenocortical carcinoma. AUSTIN, TEXAS, April 3, 2024 – Qana Therapeutics, an Austin-based biotechnology company, has received a 2024 National Institutes of Health’s Small Business...
by admin | Aug 25, 2023 | Company news
Proprietary delivery platform, based on endogenous human cholesterol transport, offers the potential to enable novel medicines across a broad range of modalities and therapeutic areas. New funding raised from life sciences investor Research Bridge Partners. AUSTIN,...
by admin | May 25, 2023 | Company news
Collaborative preclinical study with Dr. Jason Yustein of Emory University funded by the Rutledge Cancer Foundation. FT WORTH, TEXAS, May 5, 2023, — Rutledge Cancer Foundation (RCF) granted $100,000 to Jason Yustein’s lab at Emory University. Yustein and his...
Recent Comments